Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.2M Buy
56,016
+7,788
+16% +$912K 0.73% 30
2026
Q1
$5.8M Sell
48,228
-761
-2% -$87.9K 0.66% 34
2025
Q4
$5.16M Buy
48,989
+9,205
+23% +$864K 0.59% 35
2025
Q3
$3.34M Buy
39,784
+956
+2% +$78.7K 0.39% 60
2025
Q2
$3.07M Buy
38,828
+3,159
+9% +$251K 0.39% 64
2025
Q1
$3.2M Sell
35,669
-2,668
-7% -$249K 0.45% 57
2024
Q4
$3.81M Buy
+38,337
New +$3.95M 0.56% 43

Other funds holding MRK

Novem Group's MRK Position: Q2 2026 in Review

Novem Group increased its Merck (MRK) stake by 16% in Q2 2026, buying an estimated $912K and bringing the position to 56,016 shares worth $7.2M. The position accounts for 0.73% of the portfolio, ranked #30.

Novem Group first reported a position in MRK in Q4 2024 and has held it in 7 quarters since. 1,660 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Novem Group held 56,016 shares of Merck worth $7.2M as of Q2 2026.
  • Novem Group bought 7,788 Merck shares in Q2 2026, an estimated $912K.
  • Merck made up 0.73% of Novem Group's portfolio in Q2 2026, its #30 holding.
  • Novem Group first reported a position in Merck in Q4 2024 and has held it in 7 quarters since.
  • 1,660 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Novem Group's 13F filing for Q2 2026, filed 21 Jul 2026.